Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • EGFR
    (7)
  • Antibody-Drug Conjugates (ADCs)
    (6)
  • HER
    (5)
  • ADC Cytotoxin
    (2)
  • Drug-Linker Conjugates for ADC
    (2)
  • Topoisomerase
    (2)
  • HSP
    (1)
  • Integrin
    (1)
  • Ligands for Target Protein for PROTAC
    (1)
  • Others
    (4)
Filter
Search Result
Results for "

her2-targeting

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    23
    TargetMol | Inhibitors_Agonists
  • Compound Libraries
    2
    TargetMol | Compound_Libraries
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Inhibitory Antibodies
    13
    TargetMol | Inhibitory_Antibodies
  • PROTAC Products
    4
    TargetMol | PROTAC
  • Isotope Products
    1
    TargetMol | Isotope_Products
  • Antibody Products
    53
    TargetMol | Antibody_Products
Dxd
UNII-OQM5SD32BQ, OQM5SD32BQ, Exatecan derivative for ADC
T11249L1599440-33-1
Dxd (OQM5SD32BQ) is a potent inhibitor of DNA topoisomerase I with an IC50 of 0.31 μM. It is used as a conjugated drug of HER2-targeting ADC.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Lys-SMCC-DM1
Lys-Nε-MCC-DM1
T119171281816-04-3
Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). It contains the microtubule polymerization inhibitor DM1 as the active metabolite, which inhibits microtubule polymerization. It is commonly used in breast cancer research.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
HSP90-IN-35
T2014301207597-54-3
HSP90-IN-35 is an inhibitor targeting Hsp90, exhibiting anticancer activity. It demonstrates an IC50 ranging from 0.05 to 0.5 μM against Her2. Additionally, HSP90-IN-35 can be utilized in the synthesis of PROTAC.
  • Inquiry Price
Size
QTY
PROTAC IDO1 Degrader-1
PROTAC IDO1 Degrader-1
T373292488851-89-2
PROTAC IDO1 Degrader-1, a pioneering compound, efficiently targets indoleamine 2,3-dioxygenase 1 (IDO1) for ubiquitination and degradation by recruiting IDO1 to the CRBN E3 ligase, thereby facilitating its entry into the ubiquitin-proteasome system (UPS) with a DC50 of 2.84 μM. This compound also moderately enhances the tumor-killing efficacy of HER2 CAR-T cells[1].
  • Inquiry Price
Size
QTY